I Tried Henry Meds for Three Months. Here’s My Honest Take.
Three months on Henry Meds got one tester from sign-up to a steady weekly routine of compounded semaglutide, with real weight loss and real side effects along the way. The short verdict: the service is easy to start and the flat monthly price is honest, but the product is a compounded drug, not FDA-approved, and the support around dosing is thinner than the marketing suggests. It is a reasonable option for some people and the wrong one for others.
What is Henry Meds actually selling?
Henry Meds is a telehealth service. You fill out an intake form, a licensed clinician reviews it, and if you qualify, a prescription is written and medication ships to your door. The recurring charge bundles the visit, the medication, and shipping into one number, which is why it reads like a subscription. The core weight product is compounded semaglutide, the same molecule found in Wegovy and Ozempic, but prepared by a compounding pharmacy rather than made under an approved drug application.
That distinction is the whole story, so it is worth stating plainly. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or manufacturing quality the way it does brand drugs, and the agency has said as much in its guidance on compounding and the FDA. That does not make compounding illegitimate. It does mean the trial evidence built for the brand does not transfer automatically to the vial in your fridge.
How did the sign-up and first weeks go?
The intake took about fifteen minutes. Questions covered weight history, medical conditions, current medications, and the usual contraindication screen. The clinician review was quick, and the first shipment arrived within a week. No wait on a pharmacy line, no prior authorization paperwork, no insurance back-and-forth. For anyone who has fought a plan over a covered brand, that speed is the appeal, and it is genuine.
The first weeks were fine. Mild nausea after the first two doses, some early fullness that made large meals unappealing, and no serious problems. That pattern tracks with what the semaglutide literature describes. In the STEP 8 trial, published in early 2022, gastrointestinal effects were the most common issue on weekly semaglutide, and most were mild to moderate. The STEP 8 results are a fair reference point even though they studied the brand rather than a compounded version.
What did the scale do over three months?
Steady, unspectacular progress. Roughly seven percent of body weight over the quarter, most of it in months two and three once the dose stepped up. That is in line with the published trajectory. The STEP 3 trial paired semaglutide with intensive behavioral therapy and reported substantial loss over months, and semaglutide has repeatedly outperformed older options like liraglutide in head-to-head brand testing.
Here is the honest caveat that the sales copy skips. Weight loss on these drugs is largely conditional on staying on them. The STEP 4 trial showed that people who continued semaglutide kept losing while those switched to placebo regained, and the STEP 1 extension found participants regained about two thirds of their lost weight roughly a year after stopping. Three months is a snapshot, not a conclusion. The real question is what the next two years look like and what it costs to sustain them.
How does the cost compare with the alternatives?
The pricing was the part I liked most. A flat monthly cash figure, no insurance in the loop, and no surprise pharmacy markup. It shifts with dose and any running promotion, so the introductory rate is not the number to plan around. Budget for the ongoing price, because this is a medication people often stay on for a long time.
Henry Meds is one of several telehealth routes for compounded GLP-1 care, and it helps to see the field before committing. Ro, Hims and Hers, and Henry Meds all run compounded programs, while LillyDirect and NovoCare are the manufacturer self-pay channels for the actual brands. For readers weighing the compounded services against each other, a resource like an honest Henry Meds review lays out how the monthly pricing and clinician access stack up. The point of shopping around is not just price. It is who you can reach when something goes wrong.
| Route | Product type | What sets the price | Main limitation |
|---|---|---|---|
| Henry Meds and similar telehealth | Compounded semaglutide | Flat monthly cash fee | Not FDA-approved |
| Manufacturer self-pay (LillyDirect, NovoCare) | Brand medication | Fixed cash price from the maker | Higher, with refill conditions |
| Covered insurance benefit | Brand medication | Formulary tier and deductible | Many plans exclude weight drugs |
What are the real risks nobody advertises?
Dosing is where compounded GLP-1 services carry their sharpest edge. Some compounded products are supplied in vials that require the patient to measure a dose, and measurement mistakes happen. A poison control case series documented administration errors with compounded semaglutide, including people who drew up several times the intended amount. A broader pharmacovigilance analysis of compounded GLP-1 reports in the FDA adverse event system points the same direction: the concentration and packaging differences matter.
My take is that the clinical support was the weakest part of the experience. Messaging a clinician worked, but replies took a day or two, and for a drug where a dosing question can be urgent, that lag is not trivial. Clinicians writing about this class have flagged the same gap in guidance on what providers need to know about compounded semaglutide. If you are the kind of person who will not chase down a question, factor that in.
One more clinical note. GLP-1 medicines started as diabetes treatments, and the evidence base there is deep, as summarized in a 2019 review of drugs for type 2 diabetes. That heritage is reassuring about the molecule. It says nothing about the quality control of any single compounded batch, which is a separate matter.
Who should skip it?
Anyone whose insurance already covers a brand should exhaust that first, because a covered Wegovy or Zepbound comes with FDA oversight the compounded route lacks. Anyone who wants a hand held closely through side effects may find the messaging model frustrating. And anyone expecting the loss to stick after they stop paying is misreading the evidence. For a self-pay patient without coverage who wants a fast, predictable start and will stay engaged, it is a defensible choice.
Key takeaways
- Henry Meds was fast to start and the flat monthly price was honest, with no insurance friction.
- The product is compounded semaglutide, which is not FDA-approved and not identical to the brand.
- Three months produced steady weight loss consistent with published semaglutide trials.
- Trial data shows most lost weight returns after stopping, so plan for the long haul.
- Dosing errors are the documented risk, and clinician response times were the weak spot.
See also: Finale de la Betway Premiership: Stellenbosch vs Marumo Gallants
Frequently asked questions
Is Henry Meds a real medical service or just a subscription?
It is a telehealth service with licensed clinicians who review an intake and prescribe. The recurring charge covers the visit, the medication, and shipping, so it feels like a subscription, but a prescriber signs off on the order.
Is the semaglutide from Henry Meds the same as Wegovy?
It contains the same active molecule but it is a compounded preparation, not the FDA-approved brand. Compounded drugs do not go through the approval process that produced the published brand trials, so the two are not interchangeable in terms of regulatory oversight.
How much does Henry Meds cost per month?
Pricing is a flat monthly cash figure that varies by dose and any promotion, and insurance is not part of the model. The sustainable ongoing price matters more than any introductory rate.
Did the weight loss last?
Three months is short. Trial data on semaglutide shows meaningful loss over months, but the same research shows a large share of that weight returns after the drug stops, so any single quarter is only a snapshot.
What is the biggest risk with compounded GLP-1 services?
Dosing errors are the reported concern. Poison control centers have logged cases tied to self-measured compounded semaglutide, so clear dosing support and a reachable clinician matter more than the price.
